Acumen Pharmaceuticals Inc (ABOS NASDAQ) stock market data APIs
$1.3138
0.08(6.1%)
as of September 12, 2025
Try our APIs with
free plan!
Acumen Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts.
Prev. Close
1.3138
Open
1.3895
High
1.3895
Low
1.2974
52 wk Range
0.855-3.36
Market Cap
79 957 K
Shares Outstanding
60 573 K
Revenue
329 K
EPS
-0.68
Beta
0.137
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Acumen Pharmaceuticals Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Acumen Pharmaceuticals Inc data using free add-ons & libraries
Get Acumen Pharmaceuticals Inc Fundamental Data
Acumen Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 329 K
- EBITDA: -143 920 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-12
- EPS/Forecast: -0.51
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Acumen Pharmaceuticals Inc News
New
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
NEWTON, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amylo...
Acumen Pharmaceuticals stock maintains Buy rating at BTIG on promising Alzheimer's drug
Investing.com - BTIG has reiterated its Buy rating and $11.00 price target on Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), citing the company’s de-risked subcutaneous clinical candidate Sabirnetug fo...
Bullish Two Hundred Day Moving Average Cross - XHB
In trading on Monday, shares of the SPDR S&P Homebuilders ETF (Symbol: XHB) crossed above their 200 day moving average of $104.55, changing hands as high as $104.98 per share. SPDR S&P Homebuilders s...
Acumen Pharma Cuts Alzheimer's Trial Costs 40% With Blood Test
(RTTNews) - Acumen Pharmaceuticals (ABOS), Monday reported that using a plasma pTau217 screening assay in its Phase?2 ALTITUDE-AD study of sabirnetug reduced trial screening costs by about 40 percent ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
